Novo Nordisk Wins European Commission Nod For Wegovy Pill In Adult Obesity /Overweight

Source and reference

source on Google Add Now Novo Nordisk ( NVO ), announced that the European Commission (EC) has granted marketing authorisation for its once-daily oral semaglutide 25 mg Wegovy pill, for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, to be used alongside a reduced-calorie diet and increased physical activity. The Wegovy pill approval is based on the OASIS phase 3 clinical trial programme, which evaluated once-daily oral semaglutide at doses of 25 mg and 50 mg in patients with obesity. The global clinical phase 3 programme consisted of four trials, which enrolled approximately 1,300 adults with obesity or overweight with one or more comorbidities. Specifically, OASIS 4 was a 64-week phase 3b trial that evaluated efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity or overweight and one or...